Role of HMGB1 in Inflammatory-mediated Injury Caused by Digestive System Diseases and Its Repair_Journal of Biomedical Engineering

Authors：

WANGFucai ^1,2 ,  XIEYong ¹

1. Department of Gastroenterology, the First Affiliated Hospital of Nanchang University;Gastroenterology Institute of Jiangxi Province;Key Laboratory of Digestive Diseases of Jiangxi Province, Nanchang 330006, China;
2. Department of Immunology, Basic Medical College of Nanchang University, Nanchang 330006, China;

Corresponding author：

XIEYong, Email: xieyong_med@163.com

Keywords：

high mobility group box 1 protein; inflammation; damage; repair; digestive system diseases

DOI：

10.7507/1001-5515.20150164

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

High mobility group box 1 protein (HMGB1), a damage-associated molecular pattern, exists ubiquitously in the cells of mammals. It contributes to maintaining the structure of nucleosome and modulating transcription of gene in nuclei. Extracellular HMGB1 plays two-way roles in promoting inflammatory and tissue repair. Released actively as well as passively following cytokine stimulation during cell death, HMGB1 may act as a late inflammatory factor and an endogenous damage-associated molecular pattern recognized by its receptors. And it may mediate the occurrence, development and outcome of the inflammatory injury of digestive system diseases, such as gastric mucosal injury, inflammatory bowel-disease, liver injury, pancreatitis, and so on. This review mainly concerns the research progresses of HMGB1 in the inflammatory injury of digestive system diseases. At the same time, HMGB1 itself, or as a therapeutic target, can promote tissue repair.

Citation： WANGFucai, XIEYong. Role of HMGB1 in Inflammatory-mediated Injury Caused by Digestive System Diseases and Its Repair. Journal of Biomedical Engineering, 2015, 32(4): 919-923. doi: 10.7507/1001-5515.20150164 Copy

1.	YANG Huan,TRACEY K J.Targeting HMGB1 in inflammation[J].Biochim Biophys Acta,2010,1799(1-2):149-156.
2.	IBRAHIM Z A,ARMOUR C L,PHIPPS S,et al.RAGE and TLRs:Relatives,friends or neighbours?[J].Mol Immunol,2013,56(4):739-744.
3.	TANG Daolin,LOTZE M T.Tumor immunity times out:TIM-3 and HMGB1[J].Nat Immunol,2012,13(9):808-810.
4.	YANAI H,BAN T,TANIGUCHI T.High-mobility group box family of proteins:ligand and sensor for innate immunity[J].Trends Immunol,2012,33(12):633-640.
5.	LI Guanqiao,LIANG Xiaoyan,LOTZE M T.HMGB1:the central cytokine for all lymphoid cells[J].Front Immunol,2013,4:68.
6.	CULLY M.Connective tissue diseases:HMGB1 helps elicit anti-dsDNA antibody production in SLE[J].Nat Rev Rheumatol,2013,9(6):321.
7.	GNANASEKAR M,KALYANASUNDARAM R,ZHENG Guoxing,et al.HMGB1:A promising therapeutic target for prostate cancer[J].Prostate Cancer,2013,2013:157103.
8.	NOGUEIRA-MACHADO J A,DE OLIVEIRA VOLPE C M.HMGB-1 as a target for inflammation controlling[J].Recent Pat Endocr Metab Immune Drug Discov,2012,6(3):201-209.
9.	RADIN J N,GONZÁLEZ-RIVERA C,IVIE S E,et al.Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells[J].Infect Immun,2011,79(7):2535-2543.
10.	赵琪,郭继中,黄学文,等.幽门螺杆菌VacA蛋白体外诱导胃上皮AGS细胞内HMGB1的表达[J].临床检验杂志,2011,29(4):279-281.
11.	YE Huihui,WU Kejian,FEI Sujuan,et al.Propofol participates in gastric mucosal protection through inhibiting the toll-like receptor-4/nuclear factor kappa-B signaling pathway[J].Clin Res Hepatol Gastroenterol,2013,37(1):e3-15.
12.	VITALI R,PALONE F,CUCCHIARA S,et al.Dipotassium glycyrrhizate inhibits HMGB1-dependent inflammation and ameliorates colitis in mice[J].PLoS One,2013,8(6):e66527.
13.	TAKAISHI H,KANAI T,NAKAZAWA A,et al.Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA):accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype[J].J Gastroenterol,2012,47(9):969-977.
14.	葛文松,吴建新,范建高.高迁移率族蛋白B1-Toll样受体途径与炎症性肠病[J].胃肠病学,2013,18(7):434-436.
15.	VITALI R,STRONATI L,NEGRONI A,et al.Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease[J].Am J Gastroenterol,2011,106(11):2029-2040.
16.	黄继英,韩冰,张顺财,等.甘草酸铵通过抑制HMGB1的表达减轻ConA诱导的免疫性肝损伤[J].胃肠病学和肝病学杂志,2012,21(3):264-267.
17.	DRAGOMIR A C,LASKIN J D,LASKIN D L.Macrophage activation by factors released from acetaminophen-injured hepatocytes:Potential role of HMGB1[J].Toxicol Appl Pharmacol,2011,253(3):170-177.
18.	YANG Zhongwei,DENG Yuxiao,SU Diansan,et al.TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury[J].Lab Invest,2013,93(7):792-800.
19.	DENG Chunqing,DENG Guohong,WANG Yuming.HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection[J].World J Gastroenterol,2013,19(31):5144-5149.
20.	段学章,胡瑾华,李晨,等.血清高迁移率族蛋白1在乙型肝炎病毒相关慢加急性肝衰竭患者中的特点及其临床意义[J].中华肝脏病杂志,2013,21(6):434-437.
21.	SITIA G,IANNACONE M,MVLLER S,et al.Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice[J].J Leukoc Biol,2007,81(1):100-107.
22.	夏敏,张婷,郭继中,等.高迁移率族蛋白1在急性坏死性胰腺炎伴器官功能损害中的作用及其抗体的保护作用[J].中华胰腺病杂志,2013,13(1):32-35.
23.	LUAN Z G,ZHANG J,YIN X H,et al.Ethyl pyruvate significantly inhibits tumour necrosis factor-α,interleukin-1β and high mobility group box 1 releasing and attenuates Sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury[J].Clin Exp Immunol,2013,172(3):417-426.
24.	KONG Xiangqian,ZHANG Caiqing,JIN Xing,et al.The effect of HMGB1 A box on lung injury in mice with acute pancreatitis[J].Biofactors,2011,37(4):323-327.
25.	ANDERSSON U,TRACEY K J.HMGB1 is a therapeutic target for sterile inflammation and infection[J].Annu Rev Immunol,2011,29:139-162.
26.	FINK M P.Ethyl pyruvate[J].Curr Opin Anaesthesiol,2008,21(2):160-167.
27.	DIENER K R,AL-DASOOQI N,LOUSBERG E L,et al.The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and Cancer[J].Immunol Cell Biol,2013,91(7):443-450.
28.	BISCETTI F,GHIRLANDA G,FLEX A.Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration[J].Curr Vasc Pharmacol,2011,9(6):677-681.
29.	BENNETT-GUERRERO E,SWAMINATHAN M,GRIGORE AM,et al.A phase Ⅱ multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass[J].J Cardiothorac Vasc Anesth,2009,23(3):324-329.

1. YANG Huan,TRACEY K J.Targeting HMGB1 in inflammation[J].Biochim Biophys Acta,2010,1799(1-2):149-156.
2. IBRAHIM Z A,ARMOUR C L,PHIPPS S,et al.RAGE and TLRs:Relatives,friends or neighbours?[J].Mol Immunol,2013,56(4):739-744.
3. TANG Daolin,LOTZE M T.Tumor immunity times out:TIM-3 and HMGB1[J].Nat Immunol,2012,13(9):808-810.
4. YANAI H,BAN T,TANIGUCHI T.High-mobility group box family of proteins:ligand and sensor for innate immunity[J].Trends Immunol,2012,33(12):633-640.
5. LI Guanqiao,LIANG Xiaoyan,LOTZE M T.HMGB1:the central cytokine for all lymphoid cells[J].Front Immunol,2013,4:68.
6. CULLY M.Connective tissue diseases:HMGB1 helps elicit anti-dsDNA antibody production in SLE[J].Nat Rev Rheumatol,2013,9(6):321.
7. GNANASEKAR M,KALYANASUNDARAM R,ZHENG Guoxing,et al.HMGB1:A promising therapeutic target for prostate cancer[J].Prostate Cancer,2013,2013:157103.
8. NOGUEIRA-MACHADO J A,DE OLIVEIRA VOLPE C M.HMGB-1 as a target for inflammation controlling[J].Recent Pat Endocr Metab Immune Drug Discov,2012,6(3):201-209.
9. RADIN J N,GONZÁLEZ-RIVERA C,IVIE S E,et al.Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells[J].Infect Immun,2011,79(7):2535-2543.
10. 赵琪,郭继中,黄学文,等.幽门螺杆菌VacA蛋白体外诱导胃上皮AGS细胞内HMGB1的表达[J].临床检验杂志,2011,29(4):279-281.
11. YE Huihui,WU Kejian,FEI Sujuan,et al.Propofol participates in gastric mucosal protection through inhibiting the toll-like receptor-4/nuclear factor kappa-B signaling pathway[J].Clin Res Hepatol Gastroenterol,2013,37(1):e3-15.
12. VITALI R,PALONE F,CUCCHIARA S,et al.Dipotassium glycyrrhizate inhibits HMGB1-dependent inflammation and ameliorates colitis in mice[J].PLoS One,2013,8(6):e66527.
13. TAKAISHI H,KANAI T,NAKAZAWA A,et al.Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA):accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype[J].J Gastroenterol,2012,47(9):969-977.
14. 葛文松,吴建新,范建高.高迁移率族蛋白B1-Toll样受体途径与炎症性肠病[J].胃肠病学,2013,18(7):434-436.
15. VITALI R,STRONATI L,NEGRONI A,et al.Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease[J].Am J Gastroenterol,2011,106(11):2029-2040.
16. 黄继英,韩冰,张顺财,等.甘草酸铵通过抑制HMGB1的表达减轻ConA诱导的免疫性肝损伤[J].胃肠病学和肝病学杂志,2012,21(3):264-267.
17. DRAGOMIR A C,LASKIN J D,LASKIN D L.Macrophage activation by factors released from acetaminophen-injured hepatocytes:Potential role of HMGB1[J].Toxicol Appl Pharmacol,2011,253(3):170-177.
18. YANG Zhongwei,DENG Yuxiao,SU Diansan,et al.TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury[J].Lab Invest,2013,93(7):792-800.
19. DENG Chunqing,DENG Guohong,WANG Yuming.HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection[J].World J Gastroenterol,2013,19(31):5144-5149.
20. 段学章,胡瑾华,李晨,等.血清高迁移率族蛋白1在乙型肝炎病毒相关慢加急性肝衰竭患者中的特点及其临床意义[J].中华肝脏病杂志,2013,21(6):434-437.
21. SITIA G,IANNACONE M,MVLLER S,et al.Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice[J].J Leukoc Biol,2007,81(1):100-107.
22. 夏敏,张婷,郭继中,等.高迁移率族蛋白1在急性坏死性胰腺炎伴器官功能损害中的作用及其抗体的保护作用[J].中华胰腺病杂志,2013,13(1):32-35.
23. LUAN Z G,ZHANG J,YIN X H,et al.Ethyl pyruvate significantly inhibits tumour necrosis factor-α,interleukin-1β and high mobility group box 1 releasing and attenuates Sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury[J].Clin Exp Immunol,2013,172(3):417-426.
24. KONG Xiangqian,ZHANG Caiqing,JIN Xing,et al.The effect of HMGB1 A box on lung injury in mice with acute pancreatitis[J].Biofactors,2011,37(4):323-327.
25. ANDERSSON U,TRACEY K J.HMGB1 is a therapeutic target for sterile inflammation and infection[J].Annu Rev Immunol,2011,29:139-162.
26. FINK M P.Ethyl pyruvate[J].Curr Opin Anaesthesiol,2008,21(2):160-167.
27. DIENER K R,AL-DASOOQI N,LOUSBERG E L,et al.The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and Cancer[J].Immunol Cell Biol,2013,91(7):443-450.
28. BISCETTI F,GHIRLANDA G,FLEX A.Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration[J].Curr Vasc Pharmacol,2011,9(6):677-681.
29. BENNETT-GUERRERO E,SWAMINATHAN M,GRIGORE AM,et al.A phase Ⅱ multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass[J].J Cardiothorac Vasc Anesth,2009,23(3):324-329.

Previous Article
Research Progress of Medical Ultrasound Assessment of Placental Function
Next Article
Research Progress of Collagen-based Three-dimensional Porous Scaffolds Used in Skin Tissue Engineering

Journal of Biomedical Engineering

Role of HMGB1 in Inflammatory-mediated Injury Caused by Digestive System Diseases and Its Repair

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content